According to research, SNAI2 epigenetic silencing governs dynamic variations in SNAI2 expression, and restoring SNAI2 expression with panobinostat improves dasatinib sensitivity, indicating a new therapeutic strategy for prostate cancer (13). This evidence concerns the gene SNAI2 and prostate cancer.